Comparison between the immunoassay and high performance liquid chromatography for therapeutic monitoring of carbamazepine and phenytoine

Shaip Krasniqi¹ ²*, Markus Zeitlinger², Steffen Bauer³

¹Institute of Clinical Pharmacology, University Clinical Center of Kosovo, Prishtina, Kosovo
²Department of Clinical Pharmacology, Medical University of Vienna
³Central Institute for Lab Medicine and Biochemistry - University Clinical Center “Charité” - Berlin

*Corresponding author: shbk71@gmail.com

Abstract

Objective: To investigate the correlation of the immunoassay and chromatography method for quantitative measurement of two antiepileptic drugs (AED), carbamazepine (CBZ) and phenytoin (PHT) and determination of relation between the CBZ and its metabolite carbamazepine 10,11-epoxide (CBZ-E). Additionally we investigated whether there is a difference in the determination of serum concentration of CBZ and PHT when measured in two different labs by high performance liquid chromatography (HPLC).

Materials and methods: This study was carried out on 102 blood samples (72 CBZ and 30 PHT) collected from epileptic outpatients. Plasma concentrations of CBZ and PHT were determined by validated HPLC (Shimadzu and Agilent) and the CEDIA-immunoassay method.

Results: The correlations of serum concentrations of CBZ between CEDIA and HPLC1 and between CEDIA and HPLC2 were good (R = 0.97 for both techniques). Even better correlation was found between concentrations of CBZ measured by the two HPLC systems (R = 0.99). Similar, for PHT, we found good correlation between CEDIA and the two systems of HPLC (HPLC1 and HPLC2, R = 0.98) and between the two systems of HPLC of R =0.98. The moderate correlation coefficient was found between serum concentrations of CBZ and its metabolite CBZ-E, measured in two labs by different HPLC (R = 0.49 and 0.43, respectively; P < 0.001).

Conclusion: We observed good correlation for estimation of CBZ and PHT concentration obtained by means the immunoassay and two different HPLC. The possibility of measurement of CBZ-E could be advantage of chromatography in comparison with immunoassay.

Key words: carbamazepine; phenytoine; HPLC; immunoassay

Received: July 9, 2010 Accepted: September 7, 2010

Introduction

Antiepileptic drugs are characterized with important inter-and/or intra-individual variation in pharmacokinetics and different susceptibility to adverse reaction (1). The clinical effect of many antiepileptic drugs correlates better with blood levels than with doses (2, 3).

Up until approximately 20 years ago, anti-epileptic therapeutics were restricted to very few drugs that were developed in the first half of the 20th century, so called old antiepileptic drugs. A relatively small therapeutic index and the desirability to guide the therapy with therapeutic drug monitoring (TDM) characterize the antiepileptics of the old, but also of the newer generation (4,5).

The old antiepileptic drugs (AED) still remain valuable in the epilepsy treatment, and the optimization of therapy with these drugs through TDM is imperative.

Carbamazepine (CBZ) is considered the first-line anticonvulsant for the treatment of generalized tonic-clonic and complex partial seizures. Its use is complicated by variable absorption, auto-induction, hetero-induction of the CYP3A4 isoenzyme and its active metabolite carbamazepine-10,11-epoxide (EPO-CBZ) (6). The pharmacologic activity of the metabolite CBZ-E is similar to that of CBZ (7).

PHT is a primary anticonvulsant drug for the prophylaxis and treatment of generalized tonic-clonic and partial seizures. PHT exhibits nonlinear pharmacokinetics in the therapeutic range. All these properties of antiepileptic drugs argue the use of TDM (8,9), as the interpretation of plasma levels of...
AED in the light of the clinical situation of epileptic patients can markedly influence dose optimisation of these drugs (10).

Selecting the most appropriate analytical methods is often not easy and the choice depends on the availability of staff, expertise and equipment, the nature of the service to be provided and the range of drugs to be assayed.

The major advantage of chromatographic techniques is their flexibility and adaptability to a wide range of drugs. However, in comparison to immunoassays they are slow, labour-intensive techniques which usually demand a high degree of technical expertise. Immunoassays have higher development costs than chromatography, narrow range of drugs to be analysed and are generally more susceptible to interference to endogenous components (cross-reactivity) (11).

The objective of our study was to investigate the interchangeability of immunoassay and chromatography for the quantitative measurement of CBZ and PHT and to investigate whether measurements in two labs using different HPLC systems could result in differences in the determination of CBZ and PHT in same serum samples. Additionally we investigated the relation between the serum concentrations of CBZ and its metabolite, CBZ-E.

Materials and methods

This retrospective study was carried out on 102 blood samples collected from epileptic outpatients who were referred for routine TDM in the IMD lab-Berlin (Institute for Medical Diagnosis, Berlin, Germany). Serum concentrations of CBZ were determined in 72 samples, while the concentrations of PHT were determined in 30 serum samples. Blood samples were taken at steady state concentration of these drugs. The serum concentrations of CBZ and its metabolite CBZ-E and PHT were determined comparatively by two HPLC systems, HPLC 1 and HPLC 2 (HPLC 1: model Shimadzu LC-9A in the Institute of Clinical Pharmacology of University Clinical Center “Charite”, Berlin; HPLC 2: model Agilent 1050 HPLC-System in the Institute for Medical Diagnosis-IMD Berlin). In both institutions measurements of AED are established for routine TDM.

In the HPLC 1 we used the commercial available kit for determination of AED (Chromsystems Instruments & Chemicals GmbH, München, Germany). We used other components of kit: Mobile Phase, high resolution, 1000 mL; AED Serum calibration standard; Internal standard, 15 mL and Precipitation reagent, 5 mL. We performed a sample preparation as was described in the manual of manufacturer. The HPLC 1 parameters were:

- isocratic HPLC system with UV detector;
- injection volume 20 μL;
- flow rate: high resolution, 1.2 mL/min;
- wavelength: 204 nm;
- column temperature ambient (~25 °C).

We have used a column and precolumn of Chromsystems Instruments & Chemicals GmbH.

In the HPLC 2 we used a ClinRep® Complete Kit for AED in serum (order no. 15000; RECIPE Chemicals + Instruments GmbH, München, Germany). The Kit components of ClinRep® were: Mobile phase 1000 mL; Standard solution 3 mL; Precipitant with internal standard IS 15 mL; Serum calibrator, lyophilisate 3 mL; Sample preparation vials with reagent (lyophilisate) and D diluting solution. The procedure of sample preparation was described in the manual of ClinRep® Complete Kit.

The HPLC 2 parameters were:

- isocratic pump, flow rate 1.0 mL/min;
- 10 μL injection volume;
- injection interval 15 min;
- UV/VIS Detector 205 nm;
- HPLC-thermostat 55°C.

The concentration of CBZ and PHT of the same patient’s samples were determined consecutively by bench top immunoassay analyzer (Model MGC 240 Microgenics – Fisher Scientific, Passau, Germany). We used a Carbamazepine kit (CEDIA) and Phenytione kit (CEDIA) and Biorad controls (Immunoassay Plus Control – Lyphocheck level 1, and Lyphocheck level 2). The calibration stability (Cedia® Core TDM Multi calibrator) was controlled by daily running of controls to check the intra assay specificity. Between run coefficients of variation were < 8% for all assays in two HPLC analytical systems. Serum samples were stored at -20 °C. The statistical
analysis of relations between HPLC and immunoassay results was performed with Microsoft EXCEL® software (Analyse-it®), using the linear regression analysis and Passing-Bablok method and Bland-Altman plots (12).

For presentation of relation between the CBZ and CBZ-E we used parametric tests when the data had a Gaussian distribution (Student-t test and Pearson correlation coefficient) (13).

Results

Analysis of the results revealed that the compliance of serum concentrations of CBZ and PHT between immunoassay and HPLC and between two different HPLC (HPLC 1 and 2) is very good. We observed excellent correlation \(r = 0.97, P < 0.001\) between CBZ concentrations obtained by HPLC 1 and CEDIA (Figure 1a). The same correlation \(r = 0.97, P < 0.001\) of CBZ concentrations were found between HPLC 2 and CEDIA (Figure 1b). In the analysis of compliance between the two HPLC systems in determination of CBZ concentrations, we obtained even better correlation, \(r = 0.99, P < 0.001\) (Figure 1c).

Likewise correlations were obtained for PHT serum concentration for different analytical methods. The good correlation of PHT serum concentration for different analytical methods.
between HPLC 1 and CEDIA ($r = 0.98$, $P < 0.001$) and between HPLC 2 and CEDIA ($r = 0.98$, $P < 0.001$) is presented in figure 2a and 2b, respectively. Comparison of PHT serum concentrations obtained by two different HPLC (HPLC 1 and 2) in two different labs also showed very good correlation ($r = 0.98$, $P < 0.001$) (Figure 2c).

In addition possible differences between two different HPLC systems were further evaluated by comparison of correlations between CBZ and its metabolite, EPO-CBZ. The correlation coefficients between CBZ and EPO-CBZ measured by HPLC in two different labs are shown in the Figure 3a and 3b. The correlations between CBZ and EPO-CBZ in both HPLC systems were moderate, i.e. $r = 0.486$ ($P < 0.001$) for HPLC 1 and $r = 0.427$ ($P < 0.001$) for HPLC 2. The correlation between HPLC 1 and HPLC 2 in measurement of EPO-CBZ was good ($R = 0.88$, $P < 0.001$).

In order to compare two analytical methods and two HPLC using different commercial kit we applied the comparison by Passing-Bablok method. The detail results between different HPLC (HPLC 1 and HPLC 2) and between HPLC and immunoassay we have presented in table 1.

The agreement between HPLC 1 and HPLC 2 in the determination of CBZ, PHT and CBZ-E we have evaluated through Bland-Altman agreement. This method we used to compare the immunoassay and chromatographic method (HPLC 1 and HPLC 2) and to present difference vs. mean average (Figure 4a-c; 5a-c and 6a). The results of Passing Bablok comparison are presented in the table 1.

**Discussion**

TDM as routine service includes the measurement of serum concentrations of numerous drugs presenting widely varying chemical structures. Thus, in the TDM service a compromise has to be made between using the best method for each individual analyte and using the techniques that allow quantization of wide range of substances.

In our study besides the correlation between two analytical methods (immunoassay-CEDIA and HPLC), we attempt to present the impact of different HPLC systems with different procedures of validation. The correlation between two HPLC systems and correlation between two HPLC methods and immunoassay method (CEDIA) observed in the present study proved very satisfactory for CBZ and PHT.

The correlation coefficient of serum concentration of CBZ and PHT between the HPLC 1 and CEDIA in our study were the same (each $r = 0.974$), while the correlations of serum concentrations of CBZ and PHT between the HPLC 2 and CEDIA in our study were slightly different ($r = 0.969$ and $r = 0.990$). The above findings almost match results of Rambeck et al., who found that in the case of PHT there was a highly linear correlation ($r = 0.985$, $y = 1.13x - 0.589$) between HPLC and the Biotrack system, while in the case of CBZ, the correlation between HPLC and Biotrack system was somewhat lower ($r = 0.931$, $y = 1.29x - 0.136$) (14). Similar results of correlation have found others authors, too (15,16).

In contrast to immunoassay, the TDM of CBZ using the chromatography system enables to measure the concentrations of CBZ-E. The determination of

---

**Table 1.** Passing and Bablok Fit Comparison of CBZ, PHT and EPO-CBZ serum concentrations measured by HPLC 1, HPLC 2 and CEDIA Immunoassay (µmol/L).

<table>
<thead>
<tr>
<th>Method Comparison</th>
<th>n</th>
<th>Range (µmol/L)</th>
<th>Passing and Bablok fit</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPLC 1 vs. CEDIA (CBZ)</td>
<td>72</td>
<td>6.19–42.84</td>
<td>0.81 + 1.00x</td>
<td>-0.14–2.01</td>
</tr>
<tr>
<td>HPLC 2 vs. CEDIA (CBZ)</td>
<td>72</td>
<td>6.19–42.84</td>
<td>0.29 + 1.03x</td>
<td>-0.90–1.58</td>
</tr>
<tr>
<td>HPLC 1 vs. HPLC 2 (CBZ)</td>
<td>72</td>
<td>7.73–42.84</td>
<td>-0.33 + 1.02x</td>
<td>-1.19–1.06</td>
</tr>
<tr>
<td>HPLC 1 vs. CEDIA (PHT)</td>
<td>30</td>
<td>4.58–125.82</td>
<td>0.07 + 1.02x</td>
<td>-1.66–1.45</td>
</tr>
<tr>
<td>HPLC 2 vs. CEDIA (PHT)</td>
<td>30</td>
<td>4.58–125.82</td>
<td>-0.08 + 1.05x</td>
<td>-2.30–2.46</td>
</tr>
<tr>
<td>HPLC 1 vs. HPLC 2 (PHT)</td>
<td>30</td>
<td>6.11–118.28</td>
<td>0.04 + 1.00x</td>
<td>-1.95–1.86</td>
</tr>
<tr>
<td>HPLC1 vs. HPLC 2 (EPO–CBZ)</td>
<td>72</td>
<td>0.53–9.51</td>
<td>-0.08 + 0.82x</td>
<td>-0.41–0.19</td>
</tr>
</tbody>
</table>
**Figure 2a.** The comparison of serum concentration of PHT between CEDIA immunoassay and HPLC 1

**Figure 2b.** The comparison of serum concentration of PHT between CEDIA immunoassay and HPLC 2

**Figure 2c.** The comparison of serum concentration of PHT between HPLC 1 and HPLC 2

**Figure 3a.** Comparison between serum concentration of CBZ and CBZ-E: HPLC 1
Krasniqi S. et al. Immunoassay and HPLC for carbamazepine and phenytoine

Figure 3a. Comparison between serum concentration of CBZ and CBZ-E: HPLC 2

Figure 3b. Comparison between serum concentration of CBZ (HPLC 1) and CBZ (HPLC 2)

Figure 4a. Bland-Altman plot: Difference HPLC1 vs. CEDIA (CBZ)

Figure 4b. Bland-Altman plot: Difference HPLC2 vs. CEDIA (CBZ)
Krasniqi S. et al. Immunoassay and HPLC for carbamazepine and phenytoine

**Figure 4c.** Bland-Altman plot: Difference HPLC1 vs. HPLC2 (CBZ)

**Figure 5a.** Bland-Altman plot: Difference HPLC1 vs. CEDIA (PHT)

**Figure 5b.** Bland-Altman plot: Difference HPLC2 vs. CEDIA (PHT)

**Figure 5c.** Bland-Altman plot: Difference HPLC1 vs. HPLC2 (PHT)
CBZ-E presents an advantage in TDM concerning the fact that this metabolite has similar pharmacological activity to the parent drug (17,18), and this should be considered in the optimization of CBZ therapy (19). In our study we noted the moderate correlation between CBZ and CBZ-E level determined by HPLC 1 (r = 0.486) and HPLC 2 (r = 0.427).

Previous authors confirmed the variability of correlation between the CBZ and its metabolite, CBZ-E. Mihaly et al. presented moderate correlation coefficient of plasma concentrations of CBZ and its metabolite, CBZ-E (r = 0.495) (20). Mihaly suggested that there was a considerable inter-subject variation in the metabolism of CBZ to CBZ-E, without presenting any other possible factor. Semah et al. observed correlation between CBZ and CBZ-E plasma levels found in the mono-therapy group, but not in the poly-therapy group (21). Further we found a good correlation in determination of CBZ-E serum concentration between HPLC 1 and HPLC 2.

Unfortunately, in our study were not able to determine which serum samples present mono-therapy or poly-therapy of CBZ.

Pasing-Bablok regression and Altman – Bland plots supported the comparison between two different HPLC and between chromatography and immunoassay. The Bland-Altman scatter diagram showed the differences plotted against the averages of the two measurements, drawing the mean difference, and the limits of agreement, defined as the mean difference plus and minus 1.96 times the standard deviation of the differences. The results showed the good agreement between different measurement techniques.

**Conclusion**

The correlation between 2 analytical methods and between 2 HPLC systems is very good indicating the complementarities of results of TDM in both institutions.

The moderate correlation between CBZ and CBZ-E obtained in our study by both HPLC systems show the possible implication of other pharmacokinetic factors and possible concomitant AED that was not subject of investigation in this study. The analytical determination of CBZ-E could be advantage of chromatography in comparison with CEDIA immunoassay.

**References**


Biochemia Medica 2010;20(3):341-9
Usporedba imunokemijske metode i metode tekućinske kromatografije visoke djelotvornosti u terapeutskom promatranju karbamazepina i fenitoina

Sažetak

Uvod: Gli je bio istražiti korelaciju imunokemijske i kromatografske metode u kvantitativnom mjerenju dva antiepileptična lijeka, karbamazepina (CBZ) i fenitoina (PHT) te ustanoviti povezanost između CBZ i njegovog metabolita karbamazepin-10,11-epoksida (CBZ-E). Dodatno smo istražili metodom tekućinske kromatografije visoke djelotvornosti (engl. high performance liquid chromatography, HPLC) bi li postojale razlike u određivanju koncentracije CBZ i PHT u serumu kad bi se mjerenje vršilo u dva različita laboratorija.

Materijali i metode: Ovo je istraživanje provedeno na 102 uzorka krvi (72 za CBZ i 30 za PHT) sakupljenih od bolesnika s epilepsijom. Koncentracije CBZ i PHT u plazmi određene su validiranim metodom HPLC (na sistemima Shimadzu i Agilent) te imunokemijskom metodom CEDIA. Korelacija koncentracija CBZ u serumu između metode CEDIA i metode HPLC 1 te između metode CEDIA i metode HPLC 2 bile je dobra (r = 0,97 za obje tehnike). Još je bolja korelacija izračunata između koncentracija CBZ izmjerenih na dva HPLC sistema (r = 0,99). Slično je bilo i za PHT. Izračunali smo dobru korelaciju između metode CEDIA i dva sistema metode HPLC (HPLC 1 i HPLC 2; r = 0,98) te između dva sistema metode HPLC r = 0,98. Koeficijent korelacije između koncentracije CBZ u serumu i koncentracije njegovog metabolita CBZ-E izmjerenih u dva laboratorija primjenom različitih metoda HPLC iznosi je r = 0,49 za CBZ i r = 0,43 za CBZ-E, pri čemu je P < 0,001.

Zaključak: Pratili smo dobru korelaciju za određivanje koncentracije CBZ i PHT primjenom imunokemijske metode i metodom HPLC na dva različita sustava. Mogućnost mjerenja CBZ-E predstavlja prednost kromatografije pred imunokemijskom metodom.

Ključne riječi: karbamazepin; fenitoin; HPLC; imunokemijska metoda

Biochimica Medica 2010;20(3):341-9